Detection of Germline and Somatic Pathogenic Variants in Patients With de Novo Metastatic Breast Cancer
NCT ID: NCT05758948
Last Updated: 2023-04-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
101 participants
OBSERVATIONAL
1998-07-05
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Molecular Profiling in Prostate Cancer
NCT04983628
Genetic Characteristics of Metastatic Breast Cancer Patients
NCT04258735
Melanoma: Genomic Profiles, Molecular Markers and Therapeutic Implications
NCT05119829
Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal
NCT05530759
Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy
NCT00897481
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients diagnosed with de novo metastatic breast cancer
Blood and tissue sample from patients diagnosed with DN-MBC will be analyzed using next generation sequencing (NGS)
NGS in blood and Formalin-Fixed Paraffin-Embedded (FFPE) tissue
In patients with denovo metastatic breast cancer blood and tissue sample will be collected and then further analysed using NGS in order to detect somatic and germline pathogenic variants
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NGS in blood and Formalin-Fixed Paraffin-Embedded (FFPE) tissue
In patients with denovo metastatic breast cancer blood and tissue sample will be collected and then further analysed using NGS in order to detect somatic and germline pathogenic variants
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis of de novo MBC (histologically confirmed)
3. Age \>18 years
4. Blood samples
5. Tumor tissue block from at least on disease site, primary (preferably) or metastatic
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hellenic Society of Medical Oncology
OTHER
Hellenic Cooperative Oncology Group
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
EVANGELIA MOIROGIORGOU
Role: PRINCIPAL_INVESTIGATOR
YGEIA Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Evangelia Moirogiorgou
Athens, , Greece
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TRANS_DNM_17
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.